Background: Oxidized Low-Density Lipoprotein Receptor 1 (Ox-LDL Receptor 1) is a secreted; single-pass type II membrane protein which belongs to the C-type lectin superfamily. Ox-LDL Receptor 1 is expressed at high levels in endothelial cells and vascular-rich organs such as placenta; lung; liver; brain; aortic intima; bone marrow; spinal cord and substantia nigra. The expression of Ox-LDL Receptor 1 is induced by inflammatory cytokines such as TNF; IFNG and IL6 by pathological conditions; such as hyperlipidemia; hypertension and diabetes mellitus. Ox-LDL Receptor 1 mediates the recognition; internalization and degradation of oxidatively modified low density lipoprotein (OxLDL) by vascular endothelial cells. Ox-LDL Receptor 1 association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release; monocyte adhesion and apoptosis. Ox-LDL Receptor 1 also binds to oxLDL; which acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells; thereby participating in cell-mediated antigen cross-presentation. It also participates in inflammatory process; by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation.
Sequence: Ser61-Gln273
Purity: > 95 % as determined by reducing SDS-PAGE.
Formulation: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Endotoxin: Please contact us for more information.